- $65.22m
- $91.82m
- $70.19m
- 56
- 49
- 39
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.02 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.58% | ||
| Return on Equity | -235.02% | ||
| Operating Margin | -38.93% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 11.79 | 18.46 | 22.24 | 37.05 | 70.19 | 84.08 | 95.97 | 19.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Directors
- Mark Shaffar NEC
- Michael McGarrity CEO (54)
- Ron Kalfus CFO
- Joseph Sollee EVP (49)
- Christopher Thibodeau EVP (44)
- John Bellano OTH
- Rudi Marien NED (74)
- Jan Pensaert NED (45)
- Ruth Devenyns NID (52)
- Walter Narajowski NID (64)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 15th, 2003
- Public Since
- June 26th, 2006
- No. of Employees
- 300
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 27,288,093
- Address
- CAP Business Center, Rue d'Abhooz 31, HERSTAL, 4040
- Web
- https://mdxhealth.com/
- Phone
- +32 43642070
- Auditors
- BDO Reviseurs d Entreprises
Upcoming Events for MDXH
Q3 2024 MDxHealth SA Earnings Release
Similar to MDXH
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the MDxHealth SA share price?
As of Today at 22:00 UTC, shares in MDxHealth SA are trading at $2.63. This share price information is delayed by 15 minutes.
How has the MDxHealth SA share price performed this year?
Shares in MDxHealth SA last closed at $2.63 and the price had moved by -24.21% over the past 365 days. In terms of relative price strength the MDxHealth SA share price has underperformed the S&P500 Index by -39.69% over the past year.
What are the analyst and broker recommendations for MDxHealth SA?
The overall consensus recommendation for MDxHealth SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the MDxHealth SA dividend yield?
MDxHealth SA does not currently pay a dividend.
Does MDxHealth SA pay a dividend?
MDxHealth SA does not currently pay a dividend.
When does MDxHealth SA next pay dividends?
MDxHealth SA does not currently pay a dividend.
How do I buy MDxHealth SA shares?
To buy shares in MDxHealth SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of MDxHealth SA?
As of the previous close price of $2.63, shares in MDxHealth SA had a market capitalisation of $71.77m.
Where are MDxHealth SA shares listed?
Here are the trading details for MDxHealth SA:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MDXH
What kind of share is MDxHealth SA?
Based on an overall assessment of its quality, value and momentum MDxHealth SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a MDxHealth SA share price forecast for 2024?
The analyst consensus target price for shares in MDxHealth SA is $8.80. That is 234.6% above the last closing price of $2.63.
Analysts covering MDxHealth SA currently have a consensus Earnings Per Share (EPS) forecast of -$1.02 for the next financial year.
What is the trend in the MDxHealth SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MDxHealth SA. Over the past six months, its share price has underperformed the S&P500 Index by -39.84%.
As of the last closing price of $2.63, shares in MDxHealth SA were trading -13.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the MDxHealth SA PE Ratio?
The MDxHealth SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.63.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of MDxHealth SA?
MDxHealth SA's management team is headed by:
- Mark Shaffar - NEC
- Michael McGarrity - CEO
- Ron Kalfus - CFO
- Joseph Sollee - EVP
- Christopher Thibodeau - EVP
- John Bellano - OTH
- Rudi Marien - NED
- Jan Pensaert - NED
- Ruth Devenyns - NID
- Walter Narajowski - NID